- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02738385
Intensity Training and Cardiovascular Health in Colombian Adults (HIIT-Heart)
October 24, 2016 updated by: Robinson Ramírez-Vélez, Universidad Santo Tomas
High Intensity Interval- vs Moderate Training on Biomarkers of Endothelial and Cardiovascular Health in Adults: Effect of Postprandial Period
Several studies have shown relationship between exercise intensity and improvement cardiometabolic health.
It has been suggested that high intensity interval training and also moderate training generate positive effects on metabolic risk factors.
For these reasons, it is necessary to clarify which type of training, is more effective to improve cardiometabolic health in latinamerican population.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bogotá, Colombia
- Robinson Ramírez Vélez Ph.D
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Written informed consent.
- Interested in improving health and fitness.
Exclusion Criteria:
- Systemic infections.
- Weight loss or gain of >10% of body weight in the past 6 months for any reason.
- Currently taking medication that suppresses or stimulates appetite.
- Uncontrolled hypertension: systolic blood pressure 160 mm Hg or diastolic blood pressure 95 mm Hg on treatment.
- Gastrointestinal disease, including self-reported chronic hepatitis or cirrhosis, any episode of alcoholic hepatitis or alcoholic pancreatitis within past year inflammatory bowel disease requiring treatment in the past year, recent or significant abdominal surgery (e.g., gastrectomy).
- Asthma.
- Diagnosed diabetes (type 1 or 2), fasting impaired glucose tolerance (blood glucose 118 mg/dL), or use of any anti-diabetic medications.
- Currently taking antidepressant, steroid, or thyroid medication, unless dosage is stable (no change for 6 months).
- Any active use of illegal or illicit drugs.
- Current exerciser (>30 min organized exercise per week).
- Indication of unsuitability of current health for exercise protocol (PARQ).
- Any other conditions which, in opinion of the investigators, would adversely affect the conduct of the trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: High Intensity Interval Training
Walking on a treadmill 4min at 80-90% peak heart rate and recovery 4 min at 65% peak heart rate until expenditure of 300 kcal until the end of training.
|
Exercise will be performed at three sessions per week.
All sessions will be supervised by a trained health or exercise professional.
|
Active Comparator: Moderate Intensity Interval Training
Walking on a treadmill at 60-80% peak heart rate until expenditure of 300 kcal until the end of training.
|
Exercise will be performed at three sessions per week.
All sessions will be supervised by a trained health or exercise professional.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline in endothelial function as measured by flow-mediated vasodilation (FMD)
Time Frame: Baseline, 2 and 12 weeks immediately after the interventions ends, preceding an 'unhealthy' meal.
|
FMD will be measured using the guidelines reported by Corretti et al.
The diameter of the brachial artery will be assessed using a high-resolution ultrasound device (Siemens SG-60, USA), equipped with a 7.5 MHz linear array transducer
|
Baseline, 2 and 12 weeks immediately after the interventions ends, preceding an 'unhealthy' meal.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline in LDL Cholesterol
Time Frame: Baseline, 2 and 12 weeks immediately after the interventions ends, preceding an 'unhealthy' meal.
|
Baseline, 2 and 12 weeks immediately after the interventions ends, preceding an 'unhealthy' meal.
|
|
Change from Baseline in HDL Cholesterol
Time Frame: Baseline, 2 and 12 weeks immediately after the interventions ends, preceding an 'unhealthy' meal.
|
Baseline, 2 and 12 weeks immediately after the interventions ends, preceding an 'unhealthy' meal.
|
|
Change from Baseline in Triglycerides
Time Frame: Baseline, 2 and 12 weeks immediately after the interventions ends, preceding an 'unhealthy' meal.
|
Baseline, 2 and 12 weeks immediately after the interventions ends, preceding an 'unhealthy' meal.
|
|
Change from Baseline in Glucose
Time Frame: Baseline, 2 and 12 weeks immediately after the interventions ends, preceding an 'unhealthy' meal.
|
Baseline, 2 and 12 weeks immediately after the interventions ends, preceding an 'unhealthy' meal.
|
|
Change from Baseline in Heart rate variability
Time Frame: Baseline, 2 and 12 weeks immediately after the interventions ends, preceding an 'unhealthy' meal.
|
HRV will be performed according to current recommendations by European Society of Cardiology using an evaluated share-ware
|
Baseline, 2 and 12 weeks immediately after the interventions ends, preceding an 'unhealthy' meal.
|
Aortic pulse wave velocity (PWVao)
Time Frame: Baseline, 2 and 12 weeks immediately after the interventions ends, preceding an 'unhealthy' meal.
|
PWVao (m s-1) will be performed within 3 to 4 minutes with the oscillometric, occlusive device, the Arteriograph.
The measurement will be taken in a supine position and were accepted if the quality indicator of the recordings was within the acceptable range (i.e., if the standard deviation [SD] of the beat-to-beat measured PWVao values was less than 1.1 m/sec).
|
Baseline, 2 and 12 weeks immediately after the interventions ends, preceding an 'unhealthy' meal.
|
Change from Baseline in muscular fitness
Time Frame: Baseline, 2 and 12 weeks immediately after the interventions ends, preceding an 'unhealthy' meal.
|
Muscular fitness (MF) will be assessed using handgrip test (maximum handgrip strength assessment) using a standard adjustable handle analogue handgrip dynamometer T-18 TKK SMEDLY III®
|
Baseline, 2 and 12 weeks immediately after the interventions ends, preceding an 'unhealthy' meal.
|
Change from Baseline in Flexibility using the sit and reach test
Time Frame: Baseline, 2 and 12 weeks immediately after the interventions ends, preceding an 'unhealthy' meal.
|
It will be determined using a maximum treadmill exercise test (Precor TRM 885, Italy) following the modified Balke protocol
|
Baseline, 2 and 12 weeks immediately after the interventions ends, preceding an 'unhealthy' meal.
|
Change from Baseline in peak uptake of volume of oxygen
Time Frame: Baseline, 2 and 12 weeks immediately after the interventions ends, preceding an 'unhealthy' meal.
|
Baseline, 2 and 12 weeks immediately after the interventions ends, preceding an 'unhealthy' meal.
|
|
Change from Baseline in Blood Pressure
Time Frame: Baseline, 2 and 12 weeks immediately after the interventions ends, preceding an 'unhealthy' meal.
|
Baseline, 2 and 12 weeks immediately after the interventions ends, preceding an 'unhealthy' meal.
|
|
Change from Baseline in Body Mass Index
Time Frame: Baseline, 2 and 12 weeks immediately after the interventions ends, preceding an 'unhealthy' meal.
|
BMI will be calculated as the body weight in kilograms divided by the square of the height in meters.
|
Baseline, 2 and 12 weeks immediately after the interventions ends, preceding an 'unhealthy' meal.
|
Change from Baseline in Body Mass
Time Frame: Baseline, 2 and 12 weeks immediately after the interventions ends, preceding an 'unhealthy' meal.
|
Baseline, 2 and 12 weeks immediately after the interventions ends, preceding an 'unhealthy' meal.
|
|
Change from Baseline in Quality & satisfaction with life by SF Community - short-form survey (SF-12™) Colombian version
Time Frame: Baseline and 12 weeks immediately after the interventions ends, preceding an 'unhealthy' meal.
|
Baseline and 12 weeks immediately after the interventions ends, preceding an 'unhealthy' meal.
|
|
Augmentation index (AIx)
Time Frame: Baseline, 2 and 12 weeks immediately after the interventions ends, preceding an 'unhealthy' meal.
|
AIx (%) will be performed within 3 to 4 minutes with the oscillometric, occlusive device, the Arteriograph.
The measurement will be taken in a supine position and were accepted if the quality indicator of the recordings was within the acceptable range (i.e., if the standard deviation [SD] of the beat-to-beat measured AIx values was less than 1.1 m/sec).
|
Baseline, 2 and 12 weeks immediately after the interventions ends, preceding an 'unhealthy' meal.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Robinson Ramírez Vélez, Ph.D, Universidad del Rosario
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Ramirez-Velez R, Tordecilla-Sanders A, Tellez-T LA, Camelo-Prieto D, Hernandez-Quinonez PA, Correa-Bautista JE, Garcia-Hermoso A, Ramirez-Campillo R, Izquierdo M. Effect of Moderate- Versus High-Intensity Interval Exercise Training on Heart Rate Variability Parameters in Inactive Latin-American Adults: A Randomized Clinical Trial. J Strength Cond Res. 2020 Dec;34(12):3403-3415. doi: 10.1519/JSC.0000000000001833.
- Ramirez-Velez R, Hernandez-Quinones PA, Tordecilla-Sanders A, Alvarez C, Ramirez-Campillo R, Izquierdo M, Correa-Bautista JE, Garcia-Hermoso A, Garcia RG. Effectiveness of HIIT compared to moderate continuous training in improving vascular parameters in inactive adults. Lipids Health Dis. 2019 Feb 4;18(1):42. doi: 10.1186/s12944-019-0981-z.
- Ramirez-Velez R, Correa-Rodriguez M, Tordecilla-Sanders A, Aya-Aldana V, Izquierdo M, Correa-Bautista JE, Alvarez C, Garcia-Hermoso A. Exercise and postprandial lipemia: effects on vascular health in inactive adults. Lipids Health Dis. 2018 Apr 3;17(1):69. doi: 10.1186/s12944-018-0719-3.
- Ramirez-Velez R, Tordecilla-Sanders A, Tellez-T LA, Camelo-Prieto D, Hernandez-Quinonez PA, Correa-Bautista JE, Garcia-Hermoso A, Ramirez-Campillo R, Izquierdo M. Similar cardiometabolic effects of high- and moderate-intensity training among apparently healthy inactive adults: a randomized clinical trial. J Transl Med. 2017 May 30;15(1):118. doi: 10.1186/s12967-017-1216-6. Erratum In: J Transl Med. 2017 Jun 13;15(1):136.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2015
Primary Completion (Actual)
October 1, 2016
Study Completion (Actual)
October 1, 2016
Study Registration Dates
First Submitted
March 23, 2016
First Submitted That Met QC Criteria
April 8, 2016
First Posted (Estimate)
April 14, 2016
Study Record Updates
Last Update Posted (Estimate)
October 25, 2016
Last Update Submitted That Met QC Criteria
October 24, 2016
Last Verified
October 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 01-1802-2013
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metabolic Diseases
-
Mondelēz International, Inc.University of SydneyCompletedMetabolic DisorderAustralia
-
Asia UniversityDepartment of Health, Executive Yuan, R.O.C. (Taiwan)Completed
-
San Diego State UniversityNot yet recruitingBone Disease, Metabolic
-
Hospital Clinic of BarcelonaNovartisCompletedBone Disease, MetabolicSpain
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Stichting MetakidsCompletedInherited Metabolic DisordersNetherlands
-
Nantes University HospitalCentre de Recherche en Nutrition Humaine Ouest (CRNH)CompletedCholesterol; Metabolic Disorder | LipoproteinemiaFrance
-
Istituto Ortopedico RizzoliCompletedOsteopenia | Bone Disease, MetabolicItaly
-
Mondelēz International, Inc.University of SydneyCompletedMetabolic Disorder; Carbohydrate, Absorption, IntestineAustralia
-
PharmanexUtah State University; Texas Diabetes & Endocrinology, P.A.CompletedOther Endocrine/Nutritional/Metabolic DisorderUnited States
Clinical Trials on High Intensity Interval Training
-
University of MichiganCompletedGlucose IntoleranceUnited States
-
Universidad SurcolombianaMaciste Macias; Gilberto AstaizaRecruiting
-
Kuopio Research Institute of Exercise MedicineKuopio University Hospital; University of Basel; University of Eastern Finland; Social Insurance Institution, FinlandTerminatedUnstable Angina Pectoris | Acute Myocardial Infarction | Recurrent Myocardial InfarctionFinland
-
Cairo UniversityKasr El Aini HospitalCompletedDiabetes Mellitus, Type 2Egypt
-
Norwegian University of Science and TechnologySt. Olavs Hospital; Liverpool John Moores University; Australian Catholic UniversityCompletedPolycystic Ovary SyndromeAustralia, Norway
-
Norwegian University of Science and TechnologySt. Olavs Hospital; Liverpool John Moores University; Australian Catholic UniversityCompletedPolycystic Ovary SyndromeAustralia, Norway
-
Hunter College of City University of New YorkRecruiting
-
Université de SherbrookeRecruiting
-
Riphah International UniversityCompleted
-
Universidad Santo TomasUniversidad del Rosario; Universidad Manuela BeltránCompleted